Search research articles
Contact Us
Filters
Showing results (81-90 of 212) with videos related to
Page
of 22
Sort By:
JAMA Oncology
|
January 30, 2025
Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy
Sarah E Lochrin, Hannah L Kalvin, James W Smithy, et al.
NPJ Digital Medicine
|
January 14, 2025
Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment
Jun J Mao, Karolina Bryl, Erin F Gillespie, et al.
Journal for Immunotherapy of Cancer
|
October 27, 2021
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
Paul B Chapman, Vetri Sudar Jayaprakasam, Katherine S Panageas, et al.
JCI Insight
|
November 26, 2025
Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma
Kathryne E Marks, Alice Horisberger, Mehreen Elahee, et al.
Journal of Surgical Oncology
|
June 16, 2015
Liver resection and ablation for metastatic melanoma: A single center experience
Alexandre Doussot, Charlée Nardin, Haruyuki Takaki, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 11, 2015
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment
Ana P Kiess, Jedd D Wolchok, Christopher A Barker, et al.
Head & Neck
|
April 5, 2016
Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response
Robert M Samstein, Richard D Carvajal, Michael A Postow, et al.
Cancer
|
October 5, 2019
High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy
Edmund K Bartlett, Jessica R Flynn, Katherine S Panageas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 9, 2025
Management and Outcomes of Clostridioides difficile Infection in Patients on Immune Checkpoint Inhibitors
Patrick T Magahis, Deepika Satish, Mini Kamboj, et al.
JAMA Oncology
|
August 18, 2017
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Alexander N Shoushtari, Claire F Friedman, Pedram Navid-Azarbaijani, et al.
Page
of 22
Search research articles
Search
Showing results (81-90 of 212) with videos related to
Sort By:
Page
of 22
JAMA Oncology
|
January 30, 2025
Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy
Sarah E Lochrin, Hannah L Kalvin, James W Smithy, et al.
NPJ Digital Medicine
|
January 14, 2025
Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment
Jun J Mao, Karolina Bryl, Erin F Gillespie, et al.
Journal for Immunotherapy of Cancer
|
October 27, 2021
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
Paul B Chapman, Vetri Sudar Jayaprakasam, Katherine S Panageas, et al.
JCI Insight
|
November 26, 2025
Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma
Kathryne E Marks, Alice Horisberger, Mehreen Elahee, et al.
Journal of Surgical Oncology
|
June 16, 2015
Liver resection and ablation for metastatic melanoma: A single center experience
Alexandre Doussot, Charlée Nardin, Haruyuki Takaki, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 11, 2015
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment
Ana P Kiess, Jedd D Wolchok, Christopher A Barker, et al.
Head & Neck
|
April 5, 2016
Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response
Robert M Samstein, Richard D Carvajal, Michael A Postow, et al.
Cancer
|
October 5, 2019
High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy
Edmund K Bartlett, Jessica R Flynn, Katherine S Panageas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 9, 2025
Management and Outcomes of Clostridioides difficile Infection in Patients on Immune Checkpoint Inhibitors
Patrick T Magahis, Deepika Satish, Mini Kamboj, et al.
JAMA Oncology
|
August 18, 2017
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Alexander N Shoushtari, Claire F Friedman, Pedram Navid-Azarbaijani, et al.
Page
of 22